share_log

HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $20

Benzinga ·  Nov 27, 2023 07:26

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $25 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment